Discovery and Structure Enabled Synthesis of 2,6-Diaminopyrimidin-4-one IRAK4 Inhibitors

ACS Medicinal Chemistry Letters

Volumn 6, Issue 8, 2015, Pages 942-947

  Seganish, W Michael ^a   Fischmann, Thierry O ^a   Sherborne, Brad ^a   Matasi, Julius ^a   Lavey, Brian ^a   McElroy, William T ^a   Tulshian, Deen ^a   Tata, James ^a   Sondey, Christopher ^a   Garlisi, Charles G ^a   Devito, Kristine ^a   Fossetta, James ^a   Lundell, Daniel ^a   Niu, Xiaoda ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

inflammation; IRAK4; kinase inhibitor; structure based drug design

Indexed keywords

2,6 DIAMINOPYRIMIDIN 4 ONE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 1BETA; PROTEIN SERINE THREONINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYDROGEN BOND; IC50; INHIBITION KINETICS; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ANALYSIS;

RATTUS;

EID: 84938918236     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00279     Document Type: Article

References (15)

1. Staschke, K. A.; Dong, S.; Saba, J.; Zhao, J.; Brooks, N. A.; Hepburn, D. L.; Xia, J.; Gulen, M. F.; Kang, Z.; Altuntas, C. Z.; Tuohy, V. K.; Gilmour, R.; Li, X.; Na, S. IRAK4 Kinase Activity Is Required for Th17 Differentiation and Th17-Mediated Disease J. Immunol. 2009, 183, 568-577 10.4049/jimmunol.0802361
2. Song, K. W.; Talamas, F. X.; Suttmann, R. T.; Olson, P. S.; Barnett, J. W.; Lee, S. W.; Thompson, K. D.; Jin, S.; Hekmat-Nejad, M.; Cai, T. Z.; Manning, A. M.; Hill, R. J.; Wong, B. R. The kinase activities of interleukin-1 receptor associated kinase (IRAK)-1 and 4 are redundant in the control of inflammatory cytokine expression in human cells Mol. Immunol. 2009, 46, 1458-1466 10.1016/j.molimm.2008.12.012
3. Brzezinska, A. A.; Johnson, J. L.; Munafo, D. B.; Ellis, B. A.; Catz, S. D. Signaling mechanisms for Toll-like receptor-activated neutrophil exocytosis: key roles for interleukin-1-receptor-associated kinase-4 and phosphatidylinositol 3-kinase but not Toll/IL-1 receptor (TIR) domain-containing adaptor inducing IFN-beta (TRIF) Immunology 2009, 127, 386-397 10.1111/j.1365-2567.2008.02980.x
4. Akira, S.; Takeda, K. Toll-like receptor signaling Nat. Rev. Immunol. 2004, 4, 499-511 10.1038/nri1391
5. Suzuki, N.; Saito, T. IRAK-4-a shared NF-kappa B activator in innate and acquired immunity Trends Immunol. 2006, 27, 566-572 10.1016/j.it.2006.10.003
6. Koziczak-Holbro, M.; Littlewood-Evans, A.; Poellinger, B.; Kovarik, J.; Dawson, J.; Zenke, G.; Burkhart, C.; Mueller, M.; Gram, H. The Critical Role of Kinase Activity of Interleukin-1 Receptor-Associated Kinase 4 in Animal Models of Joint Inflammation Arthritis Rheum. 2009, 60, 1661-1671 10.1002/art.24552
7. Picard, C.; Puel, A.; Bonnet, M.; Ku, C. L.; Bustamante, J.; Yang, K.; Soudais, C.; Dupuis, S.; Feinberg, J.; Fieschi, C.; Elbim, C.; Hitchcock, R.; Lammas, D.; Davies, G.; Al-Ghonaium, A.; Al-Rayes, H.; Al-Jumaah, S.; Al-Hajjar, S.; Al-Mohsen, I. Z.; Frayha, H. H.; Rucker, R.; Hawn, T. R.; Aderem, A.; Tufenkeji, H.; Haraguchi, S.; Day, N. K.; Good, R. A.; Gougerot-Pocidalo, M. A.; Ozinsky, A.; Casanova, J. L. Pyogenic bacterial infections in humans with IRAK-4 deficiency Science 2003, 299, 2076-2079 10.1126/science.1081902
8. Chaudhary, D.; Robinson, S.; Romero, D. L. Recent Advances in the Discovery of Small Molecule Inhibitors of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) as a Therapeutic Target for Inflammation and Oncology Disorders J. Med. Chem. 2015, 58, 96-110 10.1021/jm5016044
9. Hynes, J.; Nair, S. K. Advances in the Discovery of Small-Molecule IRAK4 Inhibitors Annu. Rep. Med. Chem. 2014, 49, 117-133 10.1016/B978-0-12-800167-7.00009-2
10. Tumey, L. N.; Boschelli, D. H.; Bhagirath, N.; Shim, J.; Murphy, E. A.; Goodwin, D.; Bennett, E. M.; Wang, M.; Lin, L.-L.; Press, B.; Shen, M.; Frisbie, R. K.; Morgan, P.; Mohan, S.; Shin, J.; Rao, V. R. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4 Bioorg. Med. Chem. Lett. 2014, 24, 2066-2072 10.1016/j.bmcl.2014.03.056
11. McElroy, W. T.; Seganish, W. M.; Herr, R. J.; Harding, J.; Yang, J.; Yet, L.; Komanduri, V.; Prakash, K. C.; Lavey, B.; Tulshian, D.; Greenlee, W. J.; Sondey, C.; Fischmann, T.; Niu, X. Discovery and hit to lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin receptor-associated kinase 4 Bioorg. Med. Chem. Lett. 2015, 25, 1836-1841 10.1016/j.bmcl.2015.03.043
12. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431 10.1016/S1359-6446(04)03069-7
13. Seganish, W. M.; McElroy, W. T.; Herr, R. J.; Brumfield, S.; Greenlee, W. J.; Harding, J.; Komanduri, V.; Matasi, J.; Prakash, K. C.; Tulshian, D.; Yang, J.; Yet, L.; Devito, K.; Fossetta, J.; Garlisi, C. G.; Lundell, D.; Niu, X.; Sondey, C. Initial optimization and series evolution of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4 Bioorg. Med. Chem. Lett. 2015, 25, 3203-3207 10.1016/j.bmcl.2015.05.097
14. Craciun, L.; Custelcean, R.; Mager, S. Molecular structure of an isocytosine analog: Combined X-ray structural and computational study of 2-Diethylalmino-6-methyl-5-n-propyl-4(3H)-pyrimidinone Struct. Chem. 1999, 10, 303-310 10.1023/A:1022051119505
15. Gaestel, M.; Kotlyarov, A.; Kracht, M. Targeting innate immunity protein kinase signaling in inflammation Nat. Rev. Drug Discovery 2009, 8, 480-499 10.1038/nrd2829